# A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

> **NCT03473002** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 21 (actual)

## Conditions studied

- Antiviral Prophylaxis
- Respiratory Syncytial Virus Infection

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** SeVRSV Vaccine

## Key facts

- **NCT ID:** NCT03473002
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-16
- **Primary completion:** 2019-02-14
- **Final completion:** 2019-02-14
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2019-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03473002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03473002, "A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03473002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*